These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 10358186)

  • 1. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
    J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
    Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
    Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
    Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
    Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL).
    Drozdzik M; Qian C; Lasarte JJ; Bilbao R; Prieto J
    Gene Ther; 1998 Dec; 5(12):1622-30. PubMed ID: 10023441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo.
    Rensing-Ehl A; Frei K; Flury R; Matiba B; Mariani SM; Weller M; Aebischer P; Krammer PH; Fontana A
    Eur J Immunol; 1995 Aug; 25(8):2253-8. PubMed ID: 7545115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
    Winter H; Hu HM; Urba WJ; Fox BA
    J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE; Shanahan F; O'Connell J; Houston AM
    Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
    Wada A; Tada Y; Kawamura K; Takiguchi Y; Tatsumi K; Kuriyama T; Takenouchi T; O-Wang J; Tagawa M
    Cancer Gene Ther; 2007 Mar; 14(3):262-7. PubMed ID: 17053813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones.
    Esser MT; Dinglasan RD; Krishnamurthy B; Gullo CA; Graham MB; Braciale VL
    J Immunol; 1997 Jun; 158(12):5612-8. PubMed ID: 9190908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination of apoptotic Fas ligand-expressing tumors decreased antitumor responses by enhanced production of immunosuppressive cytokines.
    Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2005; 25(1A):299-303. PubMed ID: 15816551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas ligand-mediated cytotoxicity is directly responsible for apoptosis of normal CD4+ T cells responding to a bacterial superantigen.
    Ettinger R; Panka DJ; Wang JK; Stanger BZ; Ju ST; Marshak-Rothstein A
    J Immunol; 1995 May; 154(9):4302-8. PubMed ID: 7536768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastoma.
    Gross N; Balmas K; Beretta Brognara C; Tschopp J
    Med Pediatr Oncol; 2001 Jan; 36(1):111-4. PubMed ID: 11464860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
    J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
    Tada Y; O-Wang J; Wada A; Takiguchi Y; Tatsumi K; Kuriyama T; Sakiyama S; Tagawa M
    Cancer Gene Ther; 2003 Feb; 10(2):134-40. PubMed ID: 12536202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.
    Katsanis E; Xu Z; Bausero MA; Dancisak BB; Gorden KB; Davis G; Gray GS; Orchard PJ; Blazar BR
    Cancer Gene Ther; 1995 Mar; 2(1):39-46. PubMed ID: 7542553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased lymphocyte apoptosis in Fas ligand transgenic mice.
    Cheng J; Liu C; Yang P; Zhou T; Mountz JD
    J Immunol; 1997 Jul; 159(2):674-84. PubMed ID: 9218582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis.
    Waldner H; Sobel RA; Howard E; Kuchroo VK
    J Immunol; 1997 Oct; 159(7):3100-3. PubMed ID: 9317104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct in vivo transfection of antisense Fas-ligand reduces tumor growth and invasion.
    Nyhus JK; Wolford C; Feng L; Barbera-Guillem E
    Gene Ther; 2001 Feb; 8(3):209-14. PubMed ID: 11313792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ameliorating effect of anti-Fas ligand MAb on wasting disease in murine model of chronic colitis.
    Dan N; Kanai T; Totsuka T; Iiyama R; Yamazaki M; Sawada T; Miyata T; Yagita H; Okumura K; Watanabe M
    Am J Physiol Gastrointest Liver Physiol; 2003 Oct; 285(4):G754-60. PubMed ID: 12969829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.